Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “NSCLC Harboring EGFR Mutations”

86 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 86 results

Large-scale testing (Phase 3)Looking for participantsNCT07182682
What this trial is testing

Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery

Who this might be right for
Non-Small Cell Lung Cancer
Dizal (Jiangsu) Pharmaceutical Co., Ltd. 360
Early research (Phase 1)Active Not RecruitingNCT05163028
What this trial is testing

A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations

Who this might be right for
Non Small Cell Lung CancerColorectal CancerPancreatic Cancer+4 more
HUYABIO International, LLC. 42
Early research (Phase 1)Study completedNCT01859026
What this trial is testing

A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation

Who this might be right for
Lung CancerNon-Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute 43
Large-scale testing (Phase 3)Active Not RecruitingNCT05668988
What this trial is testing

DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

Who this might be right for
Non-small Cell Lung Cancer
Dizal Pharmaceuticals 324
Large-scale testing (Phase 3)Active Not RecruitingNCT04687241
What this trial is testing

Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations

Who this might be right for
Non-small Cell Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 192
Testing effectiveness (Phase 2)WithdrawnNCT04576208
What this trial is testing

Evaluate the Impact of Management Strategies on Gastrointestinal-Related Adverse Events in Participants With Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations Receiving TAK-788

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)
Takeda
Testing effectiveness (Phase 2)Study completedNCT03940703
What this trial is testing

Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

Who this might be right for
Non-small Cell Lung Cancer
EMD Serono Research & Development Institute, Inc. 140
Testing effectiveness (Phase 2)Active Not RecruitingNCT04036682
What this trial is testing

A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung CancerEGFR Exon 20 Mutation
Cullinan Therapeutics Inc. 284
Testing effectiveness (Phase 2)Ended earlyNCT02500927
What this trial is testing

ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations

Who this might be right for
EGFR-TKI-naïve Patients With NSCLC Harboring EGFR Activating Mutations
Astellas Pharma Inc 31
Testing effectiveness (Phase 2)Ended earlyNCT02192697
What this trial is testing

An Open Study of ASP8273 in Patients With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations

Who this might be right for
Non-small Cell Lung Cancer
Astellas Pharma Inc 124
Testing effectiveness (Phase 2)Active Not RecruitingNCT05463224
What this trial is testing

Lazertinib for NSCLC Harboring Activating EGFR Mutations in TKI naïve Patients

Who this might be right for
NSCLC
Sehhoon Park 150
Testing effectiveness (Phase 2)Looking for participantsNCT06276283
What this trial is testing

DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)

Who this might be right for
Non-small Cell Lung Cancer
Dizal Pharmaceuticals 60
Large-scale testing (Phase 3)Active Not RecruitingNCT03833154
What this trial is testing

Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation

Who this might be right for
Carcinoma, Non-Small-Cell Lung
AstraZeneca 724
Not applicableApproved For MarketingNCT01931306
What this trial is testing

Expanded Access Study of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim
Testing effectiveness (Phase 2)UnknownNCT04811001
What this trial is testing

Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations

Who this might be right for
NSCLC
Fondazione Ricerca Traslazionale 170
Large-scale testing (Phase 3)Temporarily pausedNCT05378763
What this trial is testing

Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations

Who this might be right for
NSCLC
Spectrum Pharmaceuticals, Inc 268
Testing effectiveness (Phase 2)Active Not RecruitingNCT05920135
What this trial is testing

First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI

Who this might be right for
EGFR Mutant Advanced Non-Small Cell Lung Cancer
Bridge Biotherapeutics, Inc. 24
Large-scale testing (Phase 3)Enrolling By InvitationNCT06281964
What this trial is testing

Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.

Who this might be right for
Non-Small-Cell Lung Cancer
Avistone Biotechnology Co., Ltd. 327
Not applicableNot Yet RecruitingNCT07714304
What this trial is testing

JS212 in Combination With JS111 as First-Line Treatment in EGFR-Mutant Advanced NSCLC

Who this might be right for
NSCLC Harboring EGFR Mutations
Huan Zhou 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT06391944
What this trial is testing

JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations

Who this might be right for
Local Advanced or Metastatic NSCLCHarboring EGFR Common Mutation
Shanghai JMT-Bio Inc. 161
Next Page